Ocugen Q4 2025 Earnings Preview
2026-03-03 11:00:09 ET
More on Ocugen
- Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data
- Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript
- Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments
- Ocugen taps Rita Johnson-Greene as CFO
- Ocugen prices $22.5M common stock offering at $1.50 per share
Read the full article on Seeking Alpha
For further details see:
Ocugen Q4 2025 Earnings PreviewNASDAQ: OCGN
OCGN Trading
-5.03% G/L:
$1.64 Last:
2,843,898 Volume:
$1.74 Open:



